Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder.
Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse-Remitting Multiple Sclerosis
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Raxone®/Catena® (idebenone)
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months.
Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Autoimmune Hepatitis-like reaction developing in a patient treated with Interferon beta 1a.
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
Antioxidant properties of the triaminopyridine, flupirtine.
The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria.

Pages